公开(公告)号：US20250043285A1

公开(公告)日：2025-02-06

申请号：US18761527

申请日：2024-07-02

Applicant: UNM Rainforest Innovations

Inventor： Vojo Deretic ,  Graham Timmins ,  Rujeena Javed

IPC: C12N15/113 ,  A61K31/357 ,  A61K31/7034 ,  A61K38/10 ,  A61K45/06 ,  A61P3/00

Abstract: The present invention relates to discovery that modulators of ATG8 and/or ATG9A act in sequence to orchestrate the sealing of autophagosomal membranes. The present invention is directed to use of these agents and this mechanism in the treatment of various disease states and/or conditions, especially cancer.

公开(公告)号：US12194032B2

公开(公告)日：2025-01-14

申请号：US17658494

申请日：2022-04-08

Applicant: ChemoCentryx, Inc.

Inventor： Zhenhua Miao ,  Thomas Schall ,  Rajinder Singh

IPC: A61K31/444 ,  A61K31/137 ,  A61K31/28 ,  A61K31/403 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/519 ,  A61K31/7034 ,  A61K35/545 ,  A61K39/395 ,  A61P13/12

Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

公开(公告)号：US20240409572A1

公开(公告)日：2024-12-12

申请号：US18259761

申请日：2021-12-23

Applicant: SARAWAK BIODIVERSITY COUNCIL

Inventor： Tiong Chia YEO ,  Julian, Cheng Liang VOONG ,  Noreha Binti MAHIDI ,  Mohd Farith bin KOTA ,  Nuraqilah binti OTHMAN ,  Michele MEJIN ,  Nyuk Fong KON ,  Mohammad Farhan Darin bin AZRI ,  Mitchel Constance ak GEORGE

IPC: C07H15/203 ,  A61K31/7034 ,  A61K36/062 ,  C12P17/06 ,  C12R1/77

Abstract: A compound, represented by formula (I): wherein R, R1, R2 and R4 are independently of one another a hydrogen atom or a C1-C6 linear or branched alkyl, or a C1-C6 linear or branched alkenyl, or a C1-C6 linear or branched alkynyl; R3 is a hydrogen atom, OR4 or a C1-C6 linear or branched alkyl, or a C1-C6 linear or branched alkenyl, or a C1-C6 linear or branched alkynyl; and n=4 to 11; its functions and isolation process thereof.

公开(公告)号：US20240342203A1

公开(公告)日：2024-10-17

申请号：US18750831

申请日：2024-06-21

Applicant: GR BIOSYSTEMS, INC.

Inventor： Andrew J. GROSS ,  Shane RIRIE

IPC: A61K31/7034 ,  A61K9/00 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

CPC classification number: A61K31/7034 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0063 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

Abstract: The present disclosure generally relates to compositions that inhibit matrix metalloproteinases (MMPs). These compositions may be particularly useful in treating oral cancer or an oropharyngeal cancer. The compositions can be prepared as a topical formulation, ointment, mouthwash, or packaged in a syringe.

公开(公告)号：US20240325356A1

公开(公告)日：2024-10-03

申请号：US18741528

申请日：2024-06-12

Applicant: Kowa Company, Ltd

Inventor： Yusuke Sasaki ,  Masato Asahiyama ,  Toshiya Tanaka

IPC: A61K31/423 ,  A61K31/7034 ,  A61K31/7048 ,  A61P1/16

CPC classification number: A61K31/423 ,  A61P1/16 ,  A61K31/7034 ,  A61K31/7048

Abstract: The present invention addresses the problem of providing a medicinal composition and a drug combination by which nonalcoholic fatty liver disease and nonalcoholic steatohepatitis can be prevented and/or treated. The present invention provides a combination of a peroxisome proliferator-activated receptor (PPAR) a agonist with a sodium glucose cotransporter 2 (SGLT2) inhibitor, which is to be used for preventing and/or treating nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：US20240226125A1

公开(公告)日：2024-07-11

申请号：US18613381

申请日：2024-03-22

Applicant: LEXICON PHARMACEUTICALS, INC.

Inventor： Phillip BANKS ,  Sangeeta SAWHNEY

IPC: A61K31/7034 ,  A61K9/00

CPC classification number: A61K31/7034 ,  A61K9/0053

Abstract: The invention relates to the use of sotagliflozin to improve glycemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥27 kg/m2.

公开(公告)号：US20240207179A1

公开(公告)日：2024-06-27

申请号：US18364273

申请日：2023-08-02

Applicant: Trait Biosciences Inc.

Inventor： Richard T. Sayre ,  Elton Carvalho Gonçalves ,  Tawanda Zidenga ,  Stephanie Willette

IPC: A61K9/00 ,  A23L33/105 ,  A23L33/125 ,  A61K9/08 ,  A61K31/7034 ,  A61K47/26 ,  A61K47/36 ,  C12G3/04

CPC classification number: A61K9/0095 ,  A23L33/105 ,  A23L33/125 ,  A61K9/08 ,  A61K31/7034 ,  A61K47/26 ,  A61K47/36 ,  C12G3/04 ,  A23V2002/00

Abstract: The present invention includes systems, methods and compositions related to the production and use of chemically modified cannabinoid food and beverage additives having enhanced water solubility and stability.

公开(公告)号：US12016871B2

公开(公告)日：2024-06-25

申请号：US17249976

申请日：2021-03-19

Applicant: GR BIOSYSTEMS, INC.

Inventor： Andrew J. Gross ,  Shane Ririe

IPC: A61K31/7034 ,  A61K9/00 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

CPC classification number: A61K31/7034 ,  A61K9/0014 ,  A61K9/0053 ,  A61K9/0063 ,  A61K31/12 ,  A61K31/121 ,  A61K31/16 ,  A61K31/4164 ,  A61K31/43 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K31/7056 ,  A61K47/34 ,  A61P35/00

Abstract: The present disclosure generally relates to compositions that inhibit matrix metalloproteinases (MMPs). These compositions may be particularly useful in treating oral cancer or an oropharyngeal cancer. The compositions can be prepared as a topical formulation, ointment, mouthwash, or packaged in a syringe.

公开(公告)号：US12016832B2

公开(公告)日：2024-06-25

申请号：US17571731

申请日：2022-01-10

Applicant: Clexio Biosciences Ltd.

Inventor： Elena Kagan ,  Gina Pastino

IPC: A61K31/135 ,  A61K9/00 ,  A61K9/16 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61P25/24

CPC classification number: A61K31/135 ,  A61K9/0053 ,  A61K9/1611 ,  A61K9/1623 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/167 ,  A61K31/136 ,  A61K31/15 ,  A61K31/343 ,  A61K31/36 ,  A61K31/381 ,  A61K31/7034 ,  A61P25/24

Abstract: The present invention provides a method for safe and efficacious administration of esketamine.

公开(公告)号：US20240189257A1

公开(公告)日：2024-06-13

申请号：US18282672

申请日：2021-03-25

Applicant: SAMI-SABINSA GROUP LIMITED

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sarang Bani ,  Anjali Pandey

IPC: A61K31/12 ,  A61K31/37 ,  A61K31/7034 ,  A61K36/185 ,  A61K36/48 ,  A61P13/12

CPC classification number: A61K31/12 ,  A61K31/37 ,  A61K31/7034 ,  A61K36/185 ,  A61K36/48 ,  A61P13/12

Abstract: The invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of nephropathy in mammals. The composition further comprises β-glucogallin and total mucic acid gallates, C-glucosides and tannins isolated from Pterocarpus marsupium. The invention also discloses the potential of the composition comprising β-glucogallin and total mucic acid gallates from Emblica officinalis, C-glucosides and tannins isolated from Pterocarpus marsupium in the therapeutic management of nephropathy.